Cambridge, UK, 29 September 2022: Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology. Incorporating AstreAdept™, the Company’s proprietary nanofiber material, this novel solution addresses the challenges associated with purifying the large and fragile products used in cell and gene therapy.
News
Collaboration to focus on new plant lines and other plant-based technologies aimed at efficient production scale-up of KBio’s current and future pipeline
ValiRx, a life science company focused on early-stage cancer therapeutics and women's health, has bolstered its drug discovery and therapeutic expertise with the appointment of Dr Cathy Tralau-Stewart as its Interim Chief Scientific Officer (CSO).
Cambridge Network celebrates a milestone birthday as it turns 25, a testament to its success as an effective and established networking organisation, operating at the heart of the Cambridge cluster.
The concept of a formalised Cambridge business networking community was a new idea when the Network was set up back in 1997 by an influential group comprising of the then Vice-Chancellor of the University, now Lord Broers, with entrepreneurs Hermann Hauser, David Cleevely, Nigel Brown, Fred Hallsworth and Anthony Ross.
Your monthly round up of employee engagement activities, read more
Click here to view the August edition of The Meeting Place
This transaction increases BioIVT's global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.
AMSBIO announce RNAdvantage – the first product in a new range of stabilization solutions that provide robust protection for your RNA samples at ambient temperature. Designed to protect and preserve RNA from most tissues, cultured cells, bacteria, and yeast for up to 14-days, RNAdvantage eliminates the traditional costs of flash freezing samples dry-ice shipping and freezer storage.
Leading global drug development consultancy Boyds has added to its team with the appointment of experienced regulatory affairs professional Katherine Bowen in response to a rise in demand for its specialist regulatory services.
With more than 14 years’ experience in regulatory affairs across both mid to large pharma and consultancies, Katherine joins Boyds as Senior Director of Regulatory Affairs.
• Stevenage Bioscience Catalyst is leading the way by introducing the Warp It recycling scheme
• The online reuse platform will enable occupier companies to donate and receive lab and office equipment, supplies and furniture
• This will reduce costs and carbon footprints for occupiers
Stevenage Bioscience Catalyst (SBC) is the first science park in the UK to sign up to the Warp It reuse platform. The platform enables companies to donate or receive surplus lab and office equipment, supplies and furniture.